|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results suggest that active vaccination against IL-5 may be a rational therapeutic approach for the treatment of asthma and potentially other eosinophilic disorders.
|
18004073 |
2008 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Role of granulocyte-macrophage colony-stimulating factor, interleukin-3 and interleukin-5 in the eosinophilia associated with T cell lymphoma.
|
8485042 |
1993 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Intravenous reslizumab, a monoclonal IL-5 antibody, is approved for treating severe asthma with eosinophilia.
|
31404668 |
2020 |
|
Eosinophilic disorder
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We recruited 284 patients with NP in four participating hospitals in Belgium and 427 healthy controls, and genotyped 10 SNPs affecting eosinophilia (rs1420101 in IL1RL1, rs12619285 in IKZF2, rs4431128 in GATA2, rs4143832 in IL5, rs3184504 in SH2B3, rs2416257 in WDR36, rs2269426 in MHC, rs9494145 in MYB, rs748065 in GFRA2, and rs3939286 in IL33) using MALDI-TOF.
|
19860791 |
2010 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Based on the data presented, I propose omalizumab for patients with an allergic phenotype regardless of their peripheral eosinophilic count, and anti-IL-5 as an alternative in allergic patients with blood eosinophilia in which omalizumab has failed; anti-IL5 for patients with an eosinophilic phenotype and omalizumab as an alternative in patients in whom anti-IL5 fails and IgE ≥30 IU/mL (compassionate use).
|
28948572 |
2017 |
|
Eosinophilic disorder
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These observations show that IL-5 plays a role in the condition, accompanied by eosinophilia, and IL-5 mRNa examination in PBMC by means of reverse transcription-polymerase chain reaction may be useful to predict the activity of eosinophilia.
|
12125504 |
2002 |
|
Eosinophilic disorder
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We describe a patient whose presenting laboratory features of elevated IgG4 and IgE and eosinophilia suggested high levels of IL-4 and IL-5 and in vivo expansion of the CD4+ Th2 subset.
|
8100845 |
1993 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-5 is a selective stimulator for the production of eosinophilia and is considered to play an important role in Kimura's disease.
|
9779259 |
1998 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
We genotyped six single-nucleotide polymorphisms (SNP) within or close to the IL5RA or IL5 genes in 82 patients with FIP1L1-PDGFRA-positive CEL plus, as controls, healthy individuals (n=100), patients with FIP1L1-PDGFRA-negative eosinophilia (n=100) or patients with chronic myeloid leukaemia (CML) (n=100).
|
17914408 |
2007 |
|
Eosinophilic disorder
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Herein, we report that intranasal delivery of IL-13 promotes IL-5-dependent esophageal eosinophilia.
|
23689305 |
2013 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Alternative strategies to inhibit eosinophilic inflammation include the use of immunostimulatory DNA sequences containing a CpG motif to act as a Th1 adjuvant to prevent Th2 responses associated with IL-5 and eosinophilia.
|
11292020 |
2001 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Interleukin 5 (IL-5) is a key cytokine in the regulation of eosinophilia and eosinophil activation in humans.
|
15474864 |
2004 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Following IL-25 administration, the IL-5(+) staining cells were CD45R/B220(+), Thy-1(+/-), but were NK1.1-, Ly-6G(GR-1)-, CD4-, CD3-, and c-kit-negative. gamma-common knockout mice did not develop eosinophilia in response to IL-25, nor were IL-5(+) cells detected.
|
12077275 |
2002 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Similarly, ST2 + IL-5+ HPC numbers were increased in the sputum of COPD patients with airway eosinophilia (p < 0.001).
|
29859068 |
2018 |
|
Eosinophilic disorder
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Exposure to mIL-17E resulted in a Th2-biased response, characterized by eosinophilia, increased serum IgE and IgG1, and a Th2 cytokine profile including elevated serum levels of IL-13 and IL-5 and elevated gene expression of IL-4, IL-5, IL-10, and IL-13 was observed in many tissues.
|
11714825 |
2001 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Transcriptional regulation of the interleukin-5 (IL-5) gene in T lymphocytes appears to be of central importance in the control of the eosinophilia characteristic of allergic responses and certain parasite infections.
|
7718877 |
1995 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-5 is a major therapeutic target to reduce eosinophilia.
|
26276876 |
2015 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
The most important cytokine involved in the induction, maintenance, and amplification of airway eosinophilia in asthma is interleukin-5 (IL-5), released by both T helper 2 (Th2) lymphocytes and group 2 innate lymphoid cells (ILC2).
|
29862274 |
2018 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Indeed, intravenous administration of IL-5Ralpha-specific ASOs not only suppressed the bone-marrow and blood eosinophilia in mice after short-term treatment with recombinant murine IL-5 but also inhibited the development of blood and tissue eosinophilia in a ragweed-induced allergic peritonitis model.
|
11159044 |
2001 |
|
Eosinophilic disorder
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition to evidence of mast cell activation, mucosa from patients with EoE have increased levels of interleukin 5; supporting eosinophilia; and upregulation of gene expression of eotaxin-3, a chemokine important in eosinophil migration.
|
31690395 |
2019 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Upstream Regulator Analysis revealed that not only T-helper 2 (Th2) and the eosinophilia-related molecules (interleukin 4 [IL4], IL5, and colony stimulating factor 2 [CSF2]) reported so far, but also cell cycle regulators (cyclin dependent kinase inhibitor 1A [CDKNA1] and cyclin D1 [CCND1]) and a tissue fibrosis-related molecule (transforming growth factor β [TGFβ]) were identified in ECRSwNP.
|
29337425 |
2018 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
As the causes of persistent eosinophilia in patients with the idiopathic hypereosinophilic syndrome (HES) are (by definition) unknown, a semi-quantitative assay for IL-5 mRNA in eosinophils and mononuclear cells was carried out using samples from 11 patients with HES.
|
7835952 |
1994 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
New therapies in the form of humanized antibodies against Th2 targets, such as anti-IgE, anti-IL4Rα, anti-IL-5 and anti-IL-13 antibodies, have shown encouraging results in terms of reduction in exacerbations and improvement in airflow in patients with a 'Th2-high' expression profile and blood eosinophilia.
|
26076339 |
2016 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
We monitored numerous alterations of eosinophils in the blood, spleen, bone marrow, and lymph nodes of interleukin-5 transgenic mice, used as an eosinophilia model, following FTY720 administration.
|
20802177 |
2010 |
|
Eosinophilic disorder
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Interestingly, <i>Il17ra<sup>-/-</sup></i> mice without the filaggrin mutation also developed spontaneous progressive skin inflammation with eosinophilia, as well as increased levels of thymic stromal lymphopoietin (TSLP) and IL-5 in the skin.
|
28615416 |
2017 |